Our next-generation virus-like particle vaccine against Epstein-Barr virus-associated diseases
Epstein-Barr virus (EBV)
Infectious Mononucleosis (IM)
Myalgic Encephalomyelits/Chronic Fatigue Syndrome (ME/CSF)
IM is an underestimated acute disease characterized by fever, pharyngitis, lymphadenopathy, fatigue and lymphocytosis. It spontaneously resolves in the majority of patients, but severe complications occur such as airway obstruction, splenic rupture, hepatitis, encephalitis, hemophagocytic lymphohistiocytosis or other serious hematological disorders.
ME/CFS commonly known as chronic fatigue is a frequent complication of Infections Mononucleosis.
Multiple Sclerosis
MS and EBV infection are strongly linked suggesting that EBV might cause this devasting disease. Infectious Mononucleosis increases the risk to suffer from MS even further.
EBV and cancer
EBV causes 1-2% of all human malignancies and causes several types of solid tumors and blood malignancies.
EBV-001 is a molecular mimic of Epstein-Barr virus
Decades of dedicated research and genetic engineering by Prof. Dr. Wolfgang Hammerschmidt (CSO) and his team at Helmholtz Munich led to a vaccine candidate that is a near perfect mimic of the virus and engineered to be very safe.
EBV-001 is a true next-generation virus-like particle and contains more than 50 EBV proteins. Our Epstein-Barr virus-like particles (EB-VLP) have a clear best-in-class potential.
EBV-001 will be developed to prevent Infectious Mononucleosis and its sequelae such as (EBV-triggered) ME/CFS.
In the long term, EBV-001 might help to reduce the frequency of Multiple Sclerosis and to treat EBV-associated cancers.
EBViously is a German academic spin-off
EBViously is a Helmholtz Munich spin-off to continue and accelerate EBV-001 vaccine development.
The project received substantial funding by the German Center for Infection Research and the Helmholtz Association.
"Our innovative Epstein-Barr virus (EBV) vaccine candidate shows promise in preventing Infectious Mononucleosis and related diseases. Incorporating a diverse array of viral antigens, including a previously overlooked EBV protein that elicits robust immune responses, our EBV-001 stands out for its potential safety and efficacy."
Prof. Dr. Wolfgang Hammerschmidt
Contact us
For questions regarding our technology and possible partnership and collaborations with EBViously please contact us via info@EBViously.com
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.